Author:
SHELLY KHILLAN ,PARNEET KAUR ,BEANT SINGH
Abstract
Placenta accreta spectrum is a rare pathology, but there is an increase in the incidence of placenta accreta. In the accreta spectrum, abnormal placental adherence to the myometrium stems in part from partial or total absence of the decidua basalis and imperfect development of the fibrinoid or Nitabuch layer. This results in the absence of a physiological line of cleavage, so resulting in failure of separation of the placenta causing significant hemorrhage. This leads to maternal morbidity and mortality. 12 patients of placenta accreta managed at Government Medical College and Rajindra Hospital, Patiala, over 1 year (December 2021–November 2022) were reported. All cases had a histopathologically proven diagnosis of placenta accreta. The major risk factors identified were placenta previa, previous cesarean section, multiparity, advanced maternal age, previous uterine surgeries, or curettage. Ultrasound (USG) color Doppler and magnetic resonance imaging allowed us to strongly suspect the presence of placenta accreta in a pregnant woman with risk factors. Placenta accreta spectrum is associated with life-threatening hemorrhage, urinary bladder injury, intensive care unit admission, massive blood transfusion, and maternal death. The course of action in each and every patient varies according to whether the diagnosis of the placenta is made antenatal or during C-section and the amount of blood loss.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference18 articles.
1. Jauniaux E, Ayres-de-Campos D, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction. Int J Gynaecol Obstet 2018;140:261-4. doi: 10.1002/ijgo.12406, PMID 29405322
2. Wong HS, Hutton J, Zuccollo J, Tait J, Pringle KC. The maternal out come in placenta accreta the significance of antenatal diagnosis and non-separation of placenta at delivery. N Z Med J 2008;121:30-8.
3. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: Twenty-year analysis. Am J Obstet Gynecol 2005;192:1458-61. doi: 10.1016/j. ajog.2004.12.074, PMID 15902137
4. Duzyj CM, Buhimschi IA, Motawea H, Laky CA, Cozzini G, Zhao G, et al. The invasive phenotype of placenta accreta extra villous trophoblasts associates with loss of E-cadherin. Placenta 2015;36:645- 51. doi: 10.1016/j.placenta.2015.04.001
5. Clouqueur E, Rubod C, Paquin A, Devisme L, Deruelle P. Placenta accreta: Diagnosis and management in a French Type-3 maternity hospital. J Gynecol Obstet Biol Reprod (Paris) 2008;37:499-504. doi: 10.1016/j.jgyn.2007.11.028, PMID 18178018